Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1

Status

Recruiting 18Completed 13Active not recruiting 5Withdrawn 3Terminated 3Not yet recruiting 3Unknown 2Suspended 1No longer available 1Approved for marketing 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5

Conditions

Leukemia, Myeloid, Acute 5Neoplasms 1

Interventions

Azacitidine 38Cytarabine 37venetoclax 34fludarabine 28Cyclophosphamide 21Daunorubicin 18fludarabine phosphate 17Decitabine 16Specimen Handling 15Tacrolimus 14Busulfan 13Injections 12Biopsy 12Melphalan 11Granulocyte Colony-Stimulating Factor 11CPX-351 11Mycophenolic Acid 10Idarubicin 10Stem Cell Transplantation 9Whole-Body Irradiation 8Etoposide 8decitabine and cedazuridine drug combination 7Thiotepa 7Mitoxantrone 7enasidenib 6Peripheral Blood Stem Cell Transplantation 6Methotrexate 6ivosidenib 5gilteritinib 5Gemtuzumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myeloid, Acute × gilteritinib × Clear all
NCT03182244 2026-05-05

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Astellas Pharma Inc

Phase 3 Active not recruiting
276 enrolled 41 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05520567 2026-03-04

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Astellas Pharma Inc

Phase 1/2 Active not recruiting
70 enrolled
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT03836209 2025-06-15

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

PrECOG, LLC.

Phase 2 Active not recruiting
181 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT04027309 2024-12-17

HOVON 156 AML

Stichting Hemato-Oncologie voor Volwassenen Nederland

Phase 3 Active not recruiting
777 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05177731 2024-10-03

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

The First Affiliated Hospital of Soochow University

Phase 3 Active not recruiting
188 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡